Unknown PHASE3 INTERVENTIONAL 2-arm NCT01413048

Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension

Phase III Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 Versus Carvedilol in Patient With Stage 1 to 2 Essential Hypertension

Sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd

Conditions Essential Hypertension

Interventions AGSCT101 12.5mg Carvedilol 25mg

Updated 6 times since 2017 Last updated: Aug 8, 2011 Started: Jan 31, 2011 Primary completion: Mar 31, 2012 Completion: Sep 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Essential Hypertension and is currently ongoing. Ahn-Gook Pharmaceuticals Co.,Ltd leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE3
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ahn-Gook Pharmaceuticals Co.,Ltd

Data source: Ahn-Gook Pharmaceuticals Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea